We’re here to advance human health, by reimagining drug discovery with the power and pace of artificial intelligence. We believe there’s a fundamental symmetry in the universe between biology and information science. And we’re building the team, and the platform, that will find it.

Isomorphic Labs was born in 2021 to apply AI and computational methods to drug discovery, and transform the way medicine helps and heals people.

Isomorphic Labs Limited [1] is a London-based company which uses artificial intelligence for drug discovery. [2] [3] [4] Isomorphic Labs was founded by Demis Hassabis, who also serves as the CEO. [5] [3] The company was incorporated on February 24, 2021 [1] and announced on November 4, 2021. [6]

Introducing Isomorphic Labs. We are reimagining the entire drug discovery process from first principles with an AI-first approach.

Jan 21, 2025 · Isomorphic Labs, the four-year-old drug discovery start-up owned by Google parent Alphabet, will have an artificial intelligence-designed drug in trials by the end of this year, says its founder ...

Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and,...

Jan 7, 2024 · Isomorphic Labs is an autonomous subsidiary of Alphabet that was launched from Alphabet's DeepMind in 2021 to build on the success of AlphaFold, the company's groundbreaking work...

Jan 10, 2024 · Isomorphic Labs uses an AI platform to predict biochemical structures, which aids the creation of new drugs by recommending which potential compounds will have the desired impact in...

Jan 8, 2024 · Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma partnerships with Eli...

Discover the latest news from, or including Isomorphic Labs. Read about our journey in redefining drug discovery with the power of AI.